A federal grand jury in the Middle District of Florida has charged two Indian nationals in connection with an alleged transnational counterfeit Ozempic distribution scheme. Swapnadip Roy, 33, and Vicky Ramancha, 37, face charges of conspiracy and smuggling related to the distribution of counterfeit prescription drugs into the United States.
According to court documents, the alleged scheme ran from at least July 2023 through April 2024. Roy and Ramancha allegedly obtained counterfeit Ozempic from unauthorized sources in China and arranged for its importation into the United States for distribution to downstream customers.
The case highlights the persistent enforcement challenges surrounding counterfeit GLP-1 medications, which have become a target for international counterfeiting operations amid rising demand for drugs like Ozempic.
What happened
According to the U.S. Department of Justice, Roy and Ramancha allegedly sourced counterfeit Ozempic from unauthorized suppliers in China. The counterfeit products reportedly included fake packaging, package inserts, pen labels, and needles designed to deceive downstream customers into believing they were purchasing authentic Ozempic authorized by the manufacturer.
The alleged scheme continued even after the U.S. Food and Drug Administration seized some counterfeit Ozempic in December 2023 and issued a public warning about counterfeit versions of the drug. One of the defendants was extradited from Italy to face charges in the United States.
The charges were brought by a federal grand jury in the Middle District of Florida. The defendants face counts related to conspiracy and smuggling.
Why it matters
This case illustrates the scale of international counterfeiting operations targeting GLP-1 drugs. The fact that the alleged scheme continued after an FDA seizure and public warning underscores the enforcement challenges posed by cross-border supply chains involving unauthorized manufacturers.
The DOJ’s enforcement action is relevant to multiple stakeholders in the GLP-1 ecosystem, including pharmaceutical distributors, telehealth platforms offering Ozempic, compounding pharmacies, and consumers.
The case also reflects federal authorities’ pursuit of transnational supply chain cases, including the extradition of a foreign national to face U.S. charges.
What to watch next
- Further court proceedings in the Middle District of Florida, including any trial schedule or plea developments.
- Potential additional enforcement actions targeting distributors or intermediaries who handled the counterfeit product.
- Continued FDA and DOJ focus on counterfeit GLP-1 supply chains, particularly those originating from unauthorized overseas sources.
- Industry responses from manufacturers, distributors, and telehealth platforms regarding supply chain verification practices.
Sources
Industry information only. Not medical or legal advice.
